PriceTargets.com logo

Aytu BioPharma - AYTU Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $9.17
  • Forecasted Upside: 309.23%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.24 As of 12/4/2025 04:59 PM ET
▲ +0.11 (5.16%)

This chart shows the closing price for AYTU by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aytu BioPharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AYTU and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AYTU

Analyst Price Target is $9.17
▲ +309.23% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Aytu BioPharma in the last 3 months. The average price target is $9.17, with a high forecast of $12.50 and a low forecast of $7.00. The average price target represents a 309.23% upside from the last price of $2.24.

This chart shows the closing price for AYTU for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 polled investment analysts is to hold stock in Aytu BioPharma. This rating has held steady since October 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/24/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
10/14/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/10/2025Zacks ResearchDowngradeHold ➝ Strong Sell
9/27/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
9/25/2025Maxim GroupLower TargetBuy ➝ Buy$9.00 ➝ $7.00
9/25/2025Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$12.00 ➝ $12.50
7/1/2025Lake Street CapitalInitiated CoverageBuy$8.00
6/30/2025Ascendiant Capital MarketsInitiated CoverageBuy$12.00
8/9/2023Maxim GroupInitiated CoverageBuy$5.00
2/22/2023Cantor FitzgeraldReiterated RatingOverweight
7/21/2022HC WainwrightLower TargetBuy$11.00 ➝ $6.00
5/17/2022Cantor FitzgeraldLower Target$11.00 ➝ $5.00
4/28/2022HC WainwrightLower TargetBuy$24.00 ➝ $11.00
6/18/2021LADENBURG THALM/SH SHReiterated RatingBuy$14.50
3/29/2021Cantor FitzgeraldInitiated CoverageOverweight$11.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.28 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 2 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Aytu BioPharma logo
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.
Read More

Today's Range

Now: $2.24
Low: $2.11
High: $2.24

50 Day Range

MA: $2.14
Low: $1.71
High: $2.51

52 Week Range

Now: $2.24
Low: $0.95
High: $2.82

Volume

51,622 shs

Average Volume

53,460 shs

Market Capitalization

$22.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.28

Frequently Asked Questions

What sell-side analysts currently cover shares of Aytu BioPharma?

The following sell-side analysts have issued reports on Aytu BioPharma in the last year: Ascendiant Capital Markets, Lake Street Capital, Maxim Group, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for AYTU.

What is the current price target for Aytu BioPharma?

0 Wall Street analysts have set twelve-month price targets for Aytu BioPharma in the last year. Their average twelve-month price target is $9.17, suggesting a possible upside of 309.2%. Ascendiant Capital Markets has the highest price target set, predicting AYTU will reach $12.50 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $7.00 for Aytu BioPharma in the next year.
View the latest price targets for AYTU.

What is the current consensus analyst rating for Aytu BioPharma?

Aytu BioPharma currently has 1 sell rating, 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AYTU, but not buy more shares or sell existing shares.
View the latest ratings for AYTU.

What other companies compete with Aytu BioPharma?

Other companies that are similar to Aytu BioPharma include Tharimmune, Leap Therapeutics, Oncobiologics, Lifevantage and Artiva Biotherapeutics. Learn More about companies similar to Aytu BioPharma.

How do I contact Aytu BioPharma's investor relations team?

Aytu BioPharma's physical mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The company's listed phone number is (720) 437-6580 and its investor relations email address is [email protected]. The official website for Aytu BioPharma is aytubio.com. Learn More about contacing Aytu BioPharma investor relations.